The role of CHKB in osteoclastic bone resorption and bone homeostasis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/634511

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Osteoporosis is a devastating disorder. Osteoporotic fractures in the elderly have been correlated with increased mortality rates. Osteoporosis alone costs $13.8 billion p.a. in USA and tens of millions of dollars in Australia. Cost to society of our ageing population for people become disabled by hip fractures alone could triple by the year 2040. Our research examines the role of CHKB in bone loss which may underscore its potential as a new molecular target for anti-resorptive drug development.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: Project Grants

Funding Amount: $565,695.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Orthopaedics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Aseptic loosening | CHKB | Osteoarthritis | Osteoclast | Osteoporosis | bone loss | bone resorption | total hip replacement

Related Links